Sec Form 4 Filing - AFEYAN NOUBAR @ BG Medicine, Inc. - 2015-07-27

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
AFEYAN NOUBAR
2. Issuer Name and Ticker or Trading Symbol
BG Medicine, Inc. [ BGMD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director X __ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O FLAGSHIP VENTURES, ONE MEMORIAL DRIVE, 7TH FLOOR
3. Date of Earliest Transaction (MM/DD/YY)
07/27/2015
(Street)
CAMBRIDGE, MA02142
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_____ Form filed by One Reporting Person
__ X __ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock ( 1 ) 07/27/2015 X( 2 ) 3,256 A $ 0.14 57,010 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 S( 2 ) 206 D $ 2.27 ( 4 ) 56,804 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 X( 5 ) 254 A $ 0.14 57,058 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 S( 5 ) 16 D $ 2.27 ( 4 ) 57,042 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 X( 6 ) 254 A $ 0.14 57,296 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 S( 6 ) 16 D $ 2.27 ( 4 ) 57,280 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 X( 7 ) 254 A $ 0.14 57,534 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 S( 7 ) 16 D $ 2.27 ( 4 ) 57,518 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 X( 8 ) 254 A $ 0.14 57,772 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 S( 8 ) 16 D $ 2.27 ( 4 ) 57,756 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 X( 9 ) 508 A $ 0.14 58,264 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 07/27/2015 S( 9 ) 32 D $ 2.27 ( 4 ) 58,232 I Held by AGTC Advisors Fund, L.P. ( 3 )
Common Stock ( 1 ) 43,930 D
Common Stock ( 1 ) 786,970 I Held by Applied Genomic Technology Capital Fund, L.P. ( 3 )
Common Stock ( 1 ) 2,508 I Held by Atlast LP ( 10 )
Common Stock ( 1 ) 441,072 I Held by Flagship Ventures Fund 2007, L.P. ( 11 )
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 3,256 ( 12 ) 07/28/2015 Common Stock 3,256 $ 0 0 I Held by AGTC Advisors Fund, L.P. ( 3 )
Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 254 ( 12 ) 09/08/2015 Common Stock 254 $ 0 0 I Held by AGTC Advisors Fund, L.P. ( 3 )
Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 254 ( 12 ) 09/28/2015 Common Stock 254 $ 0 0 I Held by AGTC Advisors Fund, L.P. ( 3 )
Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 254 ( 12 ) 11/14/2015 Common Stock 254 $ 0 0 I Held by AGTC Advisors Fund, L.P. ( 3 )
Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 254 ( 12 ) 12/15/2015 Common Stock 254 $ 0 0 I Held by AGTC Advisors Fund, L.P. ( 3 )
Warrant to Purchase Common Stock (right to buy) ( 1 ) $ 0.14 07/27/2015 X 508 ( 12 ) 03/10/2016 Common Stock 508 $ 0 0 I Held by AGTC Advisors Fund, L.P. ( 3 )
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
AFEYAN NOUBAR
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA02142
X X
Flagship Ventures Management, Inc.
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA02142
X
NewcoGen Group, Inc.
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA02142
X
AGTC ADVISORS FUND LP
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA02142
X
AGTC Partners, L.P.
C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA02142
X
Signatures
/s/ Noubar B. Afeyan, Ph.D. 07/29/2015
Signature of Reporting Person Date
/s/ Noubar B. Afeyan, Ph.D., Authorized Signatory for Flagship Ventures Management, Inc. 07/29/2015
Signature of Reporting Person Date
/s/ Noubar B. Afeyan, Ph.D., Authorized Signatory for NewcoGen Group, Inc. 07/29/2015
Signature of Reporting Person Date
/s/ Noubar B. Afeyan, Ph.D., Authorized Signatory for AGTC Advisors Fund, L.P. 07/29/2015
Signature of Reporting Person Date
/s/ Noubar B. Afeyan, Ph.D., Authorized Signatory for AGTC Partners, L.P. 07/29/2015
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Share and price per share amounts have been adjusted to reflect a 1-for-4 reverse split of the Issuer's common stock on July 8, 2015.
( 2 )On July 27, 2015, AGTC Advisors Fund, L.P. ("AGTCA") exercised warrants to purchase 3,256 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 206 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 3,050 shares.
( 3 )NewcoGen Group, Inc. ("NG") is the general partner of AGTC Partners, L.P., which is the general partner of AGTCA and Applied Genomic Technology Capital Fund, L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar B. Afeyan, Ph.D. is the director of Flagship and may be deemed to beneficially own the securities held by the AGTC Funds. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
( 4 )The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date.
( 5 )On July 27, 2015, AGTCA exercised warrants to purchase 254 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 16 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 238 shares.
( 6 )On July 27, 2015, AGTCA exercised warrants to purchase 254 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 16 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 238 shares.
( 7 )On July 27, 2015, AGTCA exercised warrants to purchase 254 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 16 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 238 shares.
( 8 )On July 27, 2015, AGTCA exercised warrants to purchase 254 shares of Comm on Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 16 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 238 shares.
( 9 )On July 27, 2015, AGTCA exercised warrants to purchase 508 shares of Common Stock for $0.14 per share. AGTCA exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 32 of the warrant shares to pay the exercise price and issuing to AGTCA the remaining 476 shares.
( 10 )Noubar B. Afeyan, Ph.D. is the general partner of Atlast LP and may be deemed to beneficially own the securities held by Atlast LP. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
( 11 )Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Dr. Afeyan and Mr. Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
( 12 )This warrant is immediately exercisable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.